An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Decoding sickle cell diseaseon January 28, 2020 at 6:51 am
The 6-year-old, whom his mom, Stephanie, describes as "wise beyond his years," has been a patient here since he was born. Every year, approximately 300,000 babies are born with sickle cell disease.
- Pfizer cans early-stage trials for cancer, sickle cell targetson January 28, 2020 at 5:36 am
The drug is aimed at sickle cell disease, caused by an inherited alteration in a gene that instructs the making of the beta-globin subunit of hemoglobin, the protein responsible for carrying oxygen in ...
- 'We’re having to scramble:' Blood bank staff say more donors needed to treat sickle cell diseaseon January 27, 2020 at 9:23 am
For many sickle cell patients in eastern Iowa, UIHC is the closest medical facility that can provide the necessary blood transfusions.
- Sickle Cell: NBA to sponsor mandatory Genotype Bill in Ekition January 27, 2020 at 8:35 am
Worried at the alarming rate young people die in the country as a result of sickle cell disease, Nigerian Bar Association(NBA), Ado -Ekiti branch has said it would sponsor a private bill that would ...
- New sickle cell drugs from Novartis, GBT need big discounts: ICER drafton January 27, 2020 at 7:18 am
When Global Blood Therapeutics won approval for its new sickle cell disease drug Oxbryta last year, execs predicted a “paradigm shift” in the way patients are treated. Now, the company is running into ...
- ICER Publish Effectiveness, Value of Therapy Reports for Sickle Cell Disease, Hemophiliaon January 24, 2020 at 2:28 pm
The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a ...
- Novartis, GBT sickle cell drugs too expensive, draft U.S. report sayson January 24, 2020 at 8:41 am
Sickle cell disease drugs made by Novartis and Global Blood Therapeutics (GBT) may not be cost effective at current prices, a draft report published on Friday suggested, widening the debate over U.S.
- Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Diseaseon January 22, 2020 at 4:00 am
/PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment ...
- 13-Year-Old With Sickle Cell Disease Pleads for Blood Donations Amid National Shortageon January 21, 2020 at 10:05 am
If you are using ad-blocking software, please disable it and reload the page. January is National Blood Donor Month, and this 13-year-old with sickle cell disease is appealing to people all around the ...
- Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trialon January 16, 2020 at 12:53 pm
Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup ...
via Bing News